Back Hlscher, C (1 Aug 2024) 'Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?' Neuropharmacology , 253, 109952
Some, like TikToker @fxshel1995, are reporting that they became pregnant after years of infertility
There are opportunities for both sides of the business: consumer and medical nutrition
The meaningful companions are behavioral rather than pharmacological: Adequate protein intake because appetite drops sharply, protecting lean mass through deliberate protein consumption is the practical priority
Disclosures: Loghman Salimzadeh: Nothing to Disclose, Stuti Shah: Nothing to Disclose, Danie La: Nothing to Disclose, Hilario Ramos: Bluejay Therapeutics: Employee, Bluejay Therapeutics: Stock privately held company, Nancy Shulman: Bluejay Therapeutics, INC: Salary and equity, Hassan Javanbakht: Nothing to Disclose, Adam Gehring: Nothing to Disclose 452 PRECLINICAL PHARMACOKINETICS OF EDP-514, AN ORAL, ONCE-DAILY ANTIVIRAL TREATMENT FOR HEPATITIS B VIRUS Meng Huang 1 Khanh Hoang 1 Jonathan Kibel 1 Shucha Zhang 1 Lisha Xu 1 Yang Li 1 Indy Zang 1 Daniel Leonard 1 Siu-Lung Chan 1 Joshua Klaene 1 Yat Sun Or 1 Li-Juan Jiang 1 , 1 Enanta Pharmaceuticals Background: Hepatitis B virus (HBV) is a global public health threat that causes approximately 1.5 million new infections every year
